The Role of Peptide YY (PYY)in Inhibiting Food Intake.

This study has been completed.
Sponsor:
Collaborator:
Aditech Pharma AB
Information provided by:
University of Copenhagen
ClinicalTrials.gov Identifier:
NCT00259233
First received: November 25, 2005
Last updated: January 20, 2009
Last verified: April 2007

November 25, 2005
January 20, 2009
March 2005
Not Provided
  • appetite
  • energy intake
Same as current
Complete list of historical versions of study NCT00259233 on ClinicalTrials.gov Archive Site
  • Plasma PYY profile
  • Blood pressure
Same as current
Not Provided
Not Provided
 
The Role of Peptide YY (PYY)in Inhibiting Food Intake.
The Effects of Peripheral Administration of Saline, PYY1-36 and PYY3-36 on ad Libitum Energy Intake and Appetite.

12 obese subjects will receive peripheral administration of placebo and 4 escalating doses of PYY1-36 and another 12 obese subjects will receive peripheral administration of placebo and 4 escalating doses PYY3-36 on 5 different test days within one week. The patients will be tested in a single blinded dose escalating protocol. Measurements of appetite, ad libitum energy intake, blood pressure and blood sampling will be performed during the test day.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment
Obesity
Drug: peripheral Peptide YY administration
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
May 2005
Not Provided

Inclusion Criteria:

  • Normal weight (BMI: 18-23 kg/m2) or 12 overweight/obese (BMI: 27-40 kg/m2)
  • Body weight fluctuations < 5 kg over the past 2 months.
  • Blood pressure normal to mildly hypertensive(<159/99 mm Hg)
  • Non-elite athletes and not planning to change physical activity during the study.

Exclusion Criteria:

  • Any physiological or psychological illnesses that could influence the study results.
  • Regular use of medicine.
  • Smoking defined as <1 cigarette per day.
  • Substance abuse or dependence.
  • Blood donation within the past 3 months before entering the study.
  • Drinking >21 alcoholic units/week.
  • Food allergies.
  • Special diets (e.g. vegetarian) or dislikes to any of the foods served during the study.
Male
20 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00259233
B208, 2
Not Provided
Not Provided
University of Copenhagen
Aditech Pharma AB
Principal Investigator: Arne Astrup, Professor Department of Human Nutrition, RVAU
University of Copenhagen
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP